
Keya Medical Announces Strategic Partnerships to Expand Coverage in the US
Keya Medical North America is set to enhance its presence in the United States through a series of strategic partnerships.
Keya Medical North America is set to enhance its presence in the United States through a series of strategic partnerships.
Advances in heart imaging and cardiovascular care. “The Depths of the Heart” by Keith Loria in Radiology Today.
Deep-learning-based, non-invasive, accurate, and accessible FFR CT analysis DEEPVESSEL FFR is now available in the USA.
Seattle, WA– April 1, 2022– Keya Medical announced that DEEPVESSEL FFR (DVFFR), has been cleared by U.S. Food and Drug Administration (FDA).
Keya Medical has received regulatory approval in China for its DeepVessel 3D Visualization Processing Software. The AI-based software medical device is designed for visualization reading of multiphase CT images and 3D models.
Keya Medical has raised $46 million in Series D funding. This funding round was led by new and existing investors, including CICC Capital, Shanghai Artificial Intelligence Investment Fund, Qianhai Gaozu Asset Management Fund, and IN CAPITAL.
Recent Comments